MetaCure

MetaCure

Founded 2003 Bermuda

Bermuda 6 employees Series B Biotechnology

MetaCure, a member of the Hobart Group companies, is focused on revolutionizing the management of type 2 diabetes. The company specializes in the development, production, and sales of the DIAMOND therapy, an innovative alternative to insulin delivery using a proprietary implantable device system. This therapy is designed for obese type 2 diabetes patients refractory to oral medication, and it has been extensively validated in clinical trials with over 300 patients. The trials have demonstrated its efficacy comparable to insulin treatment, while minimizing associated side effects and the inconvenience of frequent blood tests and injections. The DIAMOND therapy involves a pacemaker-like device implanted in the abdomen, delivering gentle electrical signals to the stomach during meals to improve glycemic control and promote weight loss. Notably, the system has achieved the CE mark and gained approval for sale in Europe, Australia, and various international markets. However, it is important to acknowledge that the DIAMOND therapy is not approved for use in the USA. Founded in 2003 and headquartered in Bermuda, MetaCure is positioned at the intersection of biotechnology and healthcare. With its groundbreaking approach to addressing the unmet needs of diabetic patients, MetaCure presents an intriguing opportunity for investors seeking to support innovations in disease management. For potential investors looking for more information, visiting the company's website at www.MetaCure.com is recommended.

FAQ About MetaCure

MetaCure, member of the Hobart Group companies, aims to provide a better way to manage type 2 diabetes, focusing on the impact on the day-to-day lives of patients. MetaCure develops, produces and sells the DIAMOND therapy, an alternative to insulin, delivered by a proprietary implantable device syst...

MetaCure was founded in 2003.

MetaCure is headquartered in Bermuda.

MetaCure operates in Biotechnology.

MetaCure has approximately 6 employees.

Top alternatives and competitors to MetaCure include ViaCyte, HYGIEIA, ReShape Lifesciences Inc., DreaMed Diabetes, Lungpacer Medical. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

MetaCure and ViaCyte are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About MetaCure

MetaCure Alternatives & Competitors

FAQ About MetaCure